Tpg Gp A LLC Takes Position in CeriBell (NASDAQ:CBLL)

TPG GP A LLC purchased a new stake in CeriBell (NASDAQ:CBLL - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 3,967,422 shares of the company's stock, valued at approximately $102,677,000. CeriBell makes up about 1.7% of TPG GP A LLC's holdings, making the stock its 12th largest position. TPG GP A LLC owned about 11.08% of CeriBell as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Legal & General Group Plc purchased a new position in shares of CeriBell during the fourth quarter worth about $32,000. Summit Investment Advisors Inc. purchased a new stake in CeriBell in the 4th quarter valued at approximately $33,000. Tower Research Capital LLC TRC purchased a new stake in CeriBell in the 4th quarter valued at approximately $37,000. BNP Paribas Financial Markets purchased a new stake in CeriBell in the 4th quarter valued at approximately $43,000. Finally, PNC Financial Services Group Inc. purchased a new stake in CeriBell in the 4th quarter valued at approximately $47,000.

CeriBell Price Performance

Shares of CBLL stock traded down $0.68 during midday trading on Friday, reaching $16.58. 211,770 shares of the company traded hands, compared to its average volume of 277,143. The firm's 50 day simple moving average is $17.15 and its two-hundred day simple moving average is $22.15. CeriBell has a 1-year low of $10.01 and a 1-year high of $32.75.

CeriBell (NASDAQ:CBLL - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.07. The company had revenue of $20.49 million for the quarter, compared to analyst estimates of $19.30 million. As a group, equities analysts expect that CeriBell will post -2.46 EPS for the current fiscal year.

Insider Buying and Selling at CeriBell

In other news, CEO Xingjuan Chao sold 5,700 shares of the business's stock in a transaction on Thursday, April 17th. The shares were sold at an average price of $15.02, for a total transaction of $85,614.00. Following the completion of the sale, the chief executive officer now directly owns 746,451 shares of the company's stock, valued at $11,211,694.02. The trade was a 0.76% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In the last three months, insiders sold 49,700 shares of company stock worth $796,434. Insiders own 20.10% of the company's stock.

Analyst Ratings Changes

CBLL has been the topic of a number of analyst reports. LADENBURG THALM/SH SH initiated coverage on CeriBell in a report on Friday, April 4th. They issued a "buy" rating and a $32.00 price objective on the stock. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $33.00 price objective on shares of CeriBell in a report on Wednesday, February 26th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $32.50.

CeriBell Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.